ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Budesonide

Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.

Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 27, 2005163 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only692 open or runningphase 4since Sep 27, 2005Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Dr. Falk Pharmaits history only171 open or runningphase 3since Mar 7, 2006Mar 7, 2006Dec 2026phase 3 · NCT06596252
Bausch Health Companiesits history only91 open or runningphase 4since Mar 17, 2020May 14, 2008Dec 2026phase 4 · NCT04314375
Takedaits history only60 open or runningphase 3since Nov 4, 2015Sep 29, 2008none ahead
AbbVieits history only50 open or runningphase 3since Dec 5, 2007Oct 30, 2007none ahead
Calliditas Therapeutics ABits history only51 open or runningphase 4since Nov 20, 2024Oct 5, 2008Mar 2027phase 4 · NCT06712407
Intech Biopharmits history only50 open or runningphase 2since Jun 11, 2014Jun 11, 2014none ahead
Chenpon Pharmaceuticalits history only30 open or runningphase 3since Aug 24, 2026Aug 24, 2026none ahead
Eurofarma Laboratoriosits history only30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Novartisits history only30 open or runningphase 4since Feb 15, 2013Feb 15, 2013none ahead
Lunan Pharmaceutical Group10 open or runningno phasesince Mar 29, 2025Mar 29, 2025none ahead

Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lunan Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 29, 2025First study: no phase study in Bioequivalence Study in Healthy SubjectsFirst studyNCT06924190 · 32 enrolled · China

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Lunan Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06924190Bioequivalence Study in Healthy Subjects · China–CompletedJan 20, 202532

How it is read

Names in the registry

  • “Budesonide”, 45 entries
  • “budesonide”, 18 entries
  • “budesonide/formoterol”, 10 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries
  • “BFF MDI 320/9.6 μg”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.